Filing Flows › Xylem (XYL) › R&D spending
Xylem (XYL) R&D spending by quarter
Xylem's R&D spending was $56.0M in Q3 2026 (third quarter 2026), -5% from Q2 2026. Over the last 7 quarters it ranged from $52.0M (Q3 2025) to $60.0M (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $56.0M | -5% | +8% |
| Q2 2026 | $59.0M | +5% | +2% |
| Q1 2026 | $56.0M | -7% | 0% |
| Q4 2025 | $60.0M | +15% | — |
| Q3 2025 | $52.0M | -10% | — |
| Q2 2025 | $58.0M | +4% | — |
| Q1 2025 | $56.0M | — | — |
Q3 2026 at a glance
Xylem, Q3 2026: revenue $2.2B (-3% year over year), operating margin 17.5%, net earnings $291M, operating cash flow $331M. The chart follows the revenue to costs, profit and cash.
Questions
What is Xylem's R&D spending?
Xylem's R&D spending was $56.0M in Q3 2026 (third quarter 2026), -5% from Q2 2026.
How has Xylem's R&D spending changed?
Over the last 7 quarters it ranged from $52.0M (Q3 2025) to $60.0M (Q4 2025).